Education
About Us
Working with TipRanks
Follow Us
STXV - AI Analysis
Top Page
Strive 1000 Value ETF (STXV)
Rating:71Outperform
Price Target:
$36.00
Positive Factors
Strong Top Holdings
Several key holdings, like Johnson & Johnson and AbbVie, have shown strong year-to-date performance, supporting the ETF’s overall returns.
Sector Diversification
The ETF is spread across multiple sectors, including Financials, Health Care, and Technology, reducing reliance on any single industry.
Low Expense Ratio
With an expense ratio of 0.18%, this ETF is cost-efficient compared to many actively managed funds.
Negative Factors
High Geographic Concentration
The ETF is heavily focused on U.S. companies, with over 99% exposure, limiting diversification across global markets.
Underperforming Holdings
Some top holdings, like UnitedHealth and Merck, have lagged in performance, which could weigh on future returns.
Moderate Asset Size
With relatively low assets under management, the ETF may face challenges in attracting liquidity and scaling effectively.
STXV vs. SPDR S&P 500 ETF (SPY)
AUM67.93M
RegionNorth America
Expense Ratio0.18%
Beta0.69
IssuerStrive
Inception DateNov 10, 2022
Dividend Yield2.49%
Asset ClassEquity
Index TrackedBloomberg US 1000 Value
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume5,819
30 Day Avg. Volume6,297
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
36.76Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering707
STXV Summary
The Strive 1000 Value ETF (Ticker: STXV) is an investment fund that focuses on large, well-established companies in the U.S. that are considered undervalued. It tracks the Bloomberg US 1000 Value Index and includes major names like Exxon Mobil and Johnson & Johnson. This ETF is designed for investors seeking stability and potential growth, as it invests in companies with strong fundamentals and a history of reliable earnings. However, since it focuses on value stocks, its performance can be affected by market trends that favor growth stocks instead.
How much will it cost me?The Strive 1000 Value ETF (Ticker: STXV) has an expense ratio of 0.18%, which means you’ll pay $1.80 per year for every $1,000 invested. This is lower than the average for actively managed funds because it is passively managed, tracking an index of large-cap value stocks.
What would affect this ETF?The Strive 1000 Value ETF could benefit from a favorable economic environment that supports value investing, such as rising interest rates, which often boost financial sector performance, or increased demand for energy and healthcare services, given its significant exposure to these sectors. However, challenges like regulatory changes affecting top holdings like Exxon Mobil or Johnson & Johnson, or economic slowdowns that impact consumer spending and cyclical sectors, could negatively affect the ETF's performance.
STXV Top 10 Holdings
The Strive 1000 Value ETF leans heavily on U.S. large-cap value stocks, with notable strength in healthcare and financials. Johnson & Johnson is a rising star, buoyed by strong earnings and growth prospects, while AbbVie adds momentum with robust R&D investments. On the flip side, UnitedHealth is lagging due to medical cost pressures, and Procter & Gamble’s slowing growth is holding back consumer defensive exposure. Energy names like Exxon Mobil and Chevron are steady contributors, but mixed signals in oil markets keep them from leading the charge. Overall, the fund’s sector diversity provides balance, though healthcare and financials drive the narrative.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Exxon Mobil | 3.04% | $2.07M | $484.99B | -4.09% | 79 Outperform | |
| Johnson & Johnson | 2.43% | $1.66M | $448.76B | 17.71% | 78 Outperform | |
| Bank of America | 2.31% | $1.57M | $391.12B | 29.59% | 70 Outperform | |
| UnitedHealth | 1.97% | $1.34M | $302.36B | -40.16% | 76 Outperform | |
| AbbVie | 1.60% | $1.09M | $374.44B | 5.73% | 59 Neutral | |
| Micron | 1.59% | $1.08M | $263.44B | 130.71% | 73 Outperform | |
| Wells Fargo | 1.56% | $1.06M | $274.04B | 37.05% | 76 Outperform | |
| Chevron | 1.52% | $1.03M | $315.38B | 0.04% | 74 Outperform | |
| Merck & Company | 1.37% | $932.28K | $206.04B | -19.02% | 79 Outperform | |
| Procter & Gamble | 1.22% | $829.14K | $345.88B | -10.33% | 74 Outperform |
STXV Technical Analysis
Neutral
―
Price Trends
32.13
Negative
31.48
Positive
30.51
Positive
Market Momentum
0.06
Positive
46.43
Neutral
11.11
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For STXV, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 32.31, equal to the 50-day MA of 32.13, and equal to the 200-day MA of 30.51, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 46.43 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for STXV.
STXV Peer Comparison
Comparison Results
Performance Comparison
STXV
Strive 1000 Value ETF
32.12
2.77
9.44%
REVS
Columbia Research Enhanced Value ETF
―
―
―
MAVF
Matrix Advisors Value ETF
―
―
―
SPVM
Invesco S&P 500 Value with Momentum ETF
―
―
―
SPDV
AAM S&P 500 High Dividend Value ETF
―
―
―
BLCV
BlackRock Large Cap Value ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents